Logo image of LUCY

INNOVATIVE EYEWEAR INC (LUCY) Stock Fundamental Analysis

NASDAQ:LUCY - Nasdaq - US45791D2080 - Common Stock - Currency: USD

1.95  +0.02 (+1.04%)

After market: 1.92 -0.03 (-1.54%)

Fundamental Rating

4

Overall LUCY gets a fundamental rating of 4 out of 10. We evaluated LUCY against 189 industry peers in the Health Care Equipment & Supplies industry. LUCY has a great financial health rating, but its profitability evaluates not so good. LUCY shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LUCY has reported negative net income.
LUCY had a negative operating cash flow in the past year.
LUCY had negative earnings in each of the past 5 years.
LUCY had a negative operating cash flow in each of the past 5 years.
LUCY Yearly Net Income VS EBIT VS OCF VS FCFLUCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -78.94%, LUCY is doing worse than 77.25% of the companies in the same industry.
LUCY has a worse Return On Equity (-85.39%) than 60.85% of its industry peers.
Industry RankSector Rank
ROA -78.94%
ROE -85.39%
ROIC N/A
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCY Yearly ROA, ROE, ROICLUCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

LUCY has a Gross Margin of 13.15%. This is amonst the worse of the industry: LUCY underperforms 80.95% of its industry peers.
In the last couple of years the Gross Margin of LUCY has declined.
The Profit Margin and Operating Margin are not available for LUCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
LUCY Yearly Profit, Operating, Gross MarginsLUCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUCY has been increased compared to 1 year ago.
The number of shares outstanding for LUCY has been reduced compared to 5 years ago.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LUCY Yearly Shares OutstandingLUCY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
LUCY Yearly Total Debt VS Total AssetsLUCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -1.16, we must say that LUCY is in the distress zone and has some risk of bankruptcy.
LUCY's Altman-Z score of -1.16 is on the low side compared to the rest of the industry. LUCY is outperformed by 60.32% of its industry peers.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACC8.83%
LUCY Yearly LT Debt VS Equity VS FCFLUCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 12.52 indicates that LUCY has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.52, LUCY belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
LUCY has a Quick Ratio of 11.40. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.40, LUCY belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.52
Quick Ratio 11.4
LUCY Yearly Current Assets VS Current LiabilitesLUCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

7

3. Growth

3.1 Past

LUCY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.12%.
Looking at the last year, LUCY shows a very strong growth in Revenue. The Revenue has grown by 42.59%.
LUCY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.36% yearly.
EPS 1Y (TTM)-5.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.52%
Revenue 1Y (TTM)42.59%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%12.13%

3.2 Future

The Earnings Per Share is expected to grow by 44.52% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 267.06% on average over the next years. This is a very strong growth
EPS Next Y69.23%
EPS Next 2Y44.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year442.11%
Revenue Next 2Y267.07%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUCY Yearly Revenue VS EstimatesLUCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
LUCY Yearly EPS VS EstimatesLUCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LUCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCY Price Earnings VS Forward Price EarningsLUCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCY Per share dataLUCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

LUCY's earnings are expected to grow with 44.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.52%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUCY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVATIVE EYEWEAR INC

NASDAQ:LUCY (5/1/2025, 9:15:02 PM)

After market: 1.92 -0.03 (-1.54%)

1.95

+0.02 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners0.88%
Inst Owner Change0%
Ins Owners40.97%
Ins Owner Change0%
Market Cap4.78M
Analysts82.86
Price Target9.18 (370.77%)
Short Float %13.83%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.33%
Min Revenue beat(2)-72.37%
Max Revenue beat(2)-32.28%
Revenue beat(4)0
Avg Revenue beat(4)-54.35%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-32.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-35.71%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)39.17%
EPS NY rev (1m)40%
EPS NY rev (3m)40%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-62.96%
Revenue NY rev (1m)-26.43%
Revenue NY rev (3m)-26.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.92
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)-6.77
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-2.86
FCFYN/A
OCF(TTM)-2.75
OCFYN/A
SpS0.67
BVpS3.71
TBVpS3.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.94%
ROE -85.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.15%
FCFM N/A
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 178.72%
Cap/Sales 16.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.52
Quick Ratio 11.4
Altman-Z -1.16
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)402.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.82%
Cap/Sales(5y)37.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.52%
EPS Next Y69.23%
EPS Next 2Y44.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)42.59%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%12.13%
Revenue Next Year442.11%
Revenue Next 2Y267.07%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.71%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.88%
OCF growth 3YN/A
OCF growth 5YN/A